4 Healthcare Stock Stories Getting Notice On Thursday

Eli Lilly and Company (NYSE:LLY): Closing price $51.85 Up

On Thursday, Lilly and Incyte Corporation announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA evaluation of baricitinib in patients suffering from active rheumatoid arthritis. Baricitinib, formerly known as LY3009104 INCB28050, is an orally-available Janus kinase inhibitor being examined for use in the treatment of certain autoimmune conditions, such as that type of arthritis. Among patients completing the open-label extension, clinical improvements seen at week 24 were sustained at the end of 52 weeks. The results were presented at the European League Against Rheumatism Annual European Congress of Rheumatology in Madrid.

Are these stocks a buy or sell? Let us help you decide. LLY